Stock Details
NVS is Novartis AG's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 83.44$. Average daily volumn in 3 months 2.15M. Market cap 166.72B



Stock symbol : NVS. Exchange : NYSE. Currency : USD
Lastest price : 76.01$. Total volume : 2.74M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Novartis AG (NVS)
Last Price
76.01$
Change
-1.13
Volume
2.74M

Previous Close77.14
Open76.30
Day Range75.53-76.62
Bid75.21 x 1.3k
Ask77.90 x 900
Volume2.74M
Average Volume2.15M
Market Cap166.72B
Beta0.49
52 Week Range75.53-94.26
Trailing P/E7.45
Foward P/E11.38
Dividend (Yield %)4.31%
Ex-Dividend Date2022-03-08



Financial Details


According to Novartis AG's financial reports the company's revenue in 2021 were 52.88B an increase( +6.12%) over the years 2020 revenue that were of 49.9B. In 2021 the company's total earnings were 24.02B while total earnings in 2020 were 8.07B( +200%).


Loading ...



Organization

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form me... dicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Market Cap:
166.72B
Revenue:
52.88B
Total Assets:
131.79B
Total Cash:
12.41B


News about "Novartis AG"

novartis-ag-nysenvs-given-average-rating-of-hold-by-brokerages-image

Novartis AG (NYSE:NVS) Given Average Rating of โ€œHoldโ€ by Brokerages

Source from : Defense World - 17 hours ago

Novartis AG (NYSE:NVS โ€“ Get Rating) has been assigned a consensus rating of โ€œHoldโ€ from the nineteen analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts ...See details»


private-advisor-group-llc-grows-stock-holdings-in-novartis-ag-nysenvs-image

Private Advisor Group LLC Grows Stock Holdings in Novartis AG (NYSE:NVS)

Source from : Defense World - 14 hours ago

Private Advisor Group LLC increased its stake in shares of Novartis AG (NYSE:NVS โ€“ Get Rating) by 9.0% during the second quarter, according to the company in its most recent disclosure with the ...See details»


Novartis to take U.S. drug patent case to Supreme Court

Source from : Reuters - 2 days ago

ZURICH, Sept 21 (Reuters) - Novartis AG (NOVN.S) plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug Gilenya after ...See details»


Novartis To Petition U.S. Supreme Court To Uphold Patent Validity Of Gilenya Dosing Regimen

Source from : Nasdaq - 3 days ago

Swiss drug major Novartis AG (NVS) announced Wednesday it plans to file a petition to the U.S. Supreme Court to uphold validity of the Gilenya (fingolimod) dosing regimen patent. The decision comes as ...See details»


novartis-planning-to-bring-dispute-over-drug-patent-to-us-supreme-court-image

Novartis Planning to Bring Dispute Over Drug Patent to U.S. Supreme Court

Source from : ph.investing.com on MSN - 3 days ago

Novartis AG (SIX:NOVN) says it plans to petition the U.S. Supreme Court to uphold the validity of its patent for a dosing regimen of its blockbuster multiple sclerosis drug Gilenya and reverse a ...See details»


Novartis escapes claim that it paid kickbacks to promote MS drug

Source from : Reuters - 11 days ago

(Reuters) - A federal judge on Tuesday dismissed, for the second time, a whistleblower lawsuit accusing drugmaker Novartis AG of paying kickbacks to doctors through a sham speaker program to ...See details»


Novartis to Petition US Supreme Court on Gilenya Patent

Source from : MarketWatch - 3 days ago

By Pierre Bertrand Novartis AG said Wednesday that it plans to file a petition with the U.S. Supreme Court to review the decision by a U.S. appeals ...See details»


novartis-says-authorities-investigating-a-patent-assertion-image

Novartis says authorities investigating a patent assertion

Source from : MarketWatch on MSN - 9 days ago

The probe into Novartis's assertion of a patent in the broader field of dermatology treatments doesn't imply wrongdoing or financial impact, the company said.See details»


Novartis AG: Diving Into the Drug Pricing Hit From the Inflation Reduction Act, Weโ€™ve Reduced Our FVEs by 2%

Source from : YAHOO!Finance - 5 days ago

Find the latest Novartis AG (NVS) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...See details»


Novartis Dodges Whistleblower Lawsuit Regarding Multiple Sclerosis Drug Kickback Claims

Source from : Yahoo - 8 days ago

A federal judge dismissed a whistleblower lawsuit accusing Novartis AG (NYSE: NVS) of paying doctors kickbacks at "sham" speaker programs to boost prescriptions of its multiple sclerosis ...See details»


Novartis statement regarding competition authority investigation into assertion of a patent

Source from : Yahoo - 9 days ago

and other risks and factors referred to in Novartis AGโ€™s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as ...See details»


Novartis to FDA: No skinny labels for Entresto

Source from : BioWorld - 5 days ago

Claiming it would be impossible to carve out a so-called skinny label that would comply with generic drug โ€œsame labelingโ€ rules, Novartis AG is petitioning the U.S. FDA, for the second time, not to ...See details»


Novartis to take U.S. drug patent case to Supreme Court

Source from : Nasdaq - 3 days ago

Novartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug Gilenya after suffering a setback in a federal appeals ...See details»


Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenyaยฎ (fingolimod) dosing regimen patent

Source from : Benzinga.com - 3 days ago

and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of ...See details»